Pelage Pharmaceuticals

Pelage Pharmaceuticals is an early-stage biotech pioneering a regenerative approach to treating hair loss by targeting the metabolic switch in hair follicle stem cells. Its lead asset, PP405, is a topical small molecule currently in Phase 2a trials for androgenetic alopecia, aiming to reactivate dormant follicles. The company differentiates itself from existing hormonal or poorly understood therapies by focusing on a novel, stem cell-centric mechanism. Backed by a team with strong scientific and clinical dermatology expertise, Pelage seeks to address a large, underserved market with significant unmet need.

Small molecule platform targeting a metabolic switch (inhibition of pyruvate oxidation/modulation of LDH activity) to activate dormant hair follicle stem cells.

Pelage competes against decades-old standards of care (minoxidil, finasteride) and procedural treatments (PRP, hair transplants). Its primary competition comes from other clinical-stage biotechs exploring new mechanisms (e.g., prostaglandin analogs, Wnt pathway activators). Its key differentiation is the direct targeting of hair follicle stem cell metabolism.